Observational studyBMC nephrology2025
Urinary NephroCheck
Observational study in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advancements in early biomarkers of acute kidney injury: from traditional indicators to a paradigm shift in lactate metabolism.Annals of medicine · 2026Review
- Early Biohumoral Detection of Acute Kidney Injury After Robotic Renal Surgery and Its Impact on Medium-Term Renal Function.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNephron-sparing surgery (NSS) represents the preferred technique to treat localized renal lesions, not being exempted from the risk of postoperative acute kidney injury (AKI) to happen, though. Patients experiencing postoperative AKI, either clinical or subclinical, are more susceptible to develop chronic kidney disease.
methodsPatients scheduled for NSS in localized renal cell carcinoma were recruited. Patients were grouped according to postoperative AKI development and postoperative NephroCheck value: group 1 (normal), no AKI and no increased biomarker; group 2 (subclinical AKI), no AKI but increased NephroCheck (> 0.3 at 4 h postoperatively); group 3, AKI and no increased NephroCheck; group 4 (clinical AKI), AKI and increased NephroCheck. Samples were collected pre- and post-operatively; renal function was re-assessed up to 24 months.
resultsAmong 131 patients included, 42% developed clinical AKI. Based on NephroCheck
conclusionsIn patients undergoing NSS, the most reliable predictor of long-term eGFR decline is represented by the occurrence of postoperative clinical AKI. In this setting, NephroCheck
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.